|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 8 (October 15), 1998:
pp. 2908-2913
Primary Myeloma Cells Growing in SCID-hu Mice: A Model for
Studying the Biology and Treatment of Myeloma and Its
Manifestations
Shmuel Yaccoby,
Bart Barlogie, and
Joshua Epstein
From the Myeloma and Transplantation Research Center, Arkansas Cancer
Research Center, University of Arkansas for Medical Sciences, Little
Rock, AR.
Progress in unraveling the biology of myeloma has suffered from lack
of an in vitro or in vivo system for reproducible growth of myeloma
cells and development of disease manifestations. The SCID-hu mouse
harbors a human microenvironment in the form of human fetal bone.
Myeloma cells from the bone marrow of 80% of patients readily grew in
the human environment of SCID-hu mice. Engraftment of myeloma cells was
followed by detectable human Ig levels in the murine blood.
Myeloma-bearing mice had high levels of monotypic human Igs, high blood
calcium levels, increased osteoclast activity, and severe resorption of
the human bones. The human microenvironment was infiltrated with
Epstein-Barr virus-negative monoclonal myeloma cells of the same
clonality as the original myeloma cells. Active angiogenesis was
apparent in areas of myeloma cell infiltration; the new endothelial
cells were of human origin. We conclude that the SCID-hu mouse is a
favorable host for studying the biology and therapy of myeloma and that
a normal bone marrow environment can support the growth of myeloma
cells.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Kirshner, K. J. Thulien, L. D. Martin, C. Debes Marun, T. Reiman, A. R. Belch, and L. M. Pilarski
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma
Blood,
October 1, 2008;
112(7):
2935 - 2945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Blood,
July 15, 2008;
112(2):
374 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Rozemuller, E. van der Spek, L. H. Bogers-Boer, M. C. Zwart, V. Verweij, M. Emmelot, R. W. Groen, R. Spaapen, A. C. Bloem, H. M. Lokhorst, et al.
A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect
Haematologica,
July 1, 2008;
93(7):
1049 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Huff and W. Matsui
Multiple Myeloma Cancer Stem Cells
J. Clin. Oncol.,
June 10, 2008;
26(17):
2895 - 2900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, P. Lin, Y. Shi, J. Romaguera, L. W. Kwak, et al.
A Severe Combined Immunodeficient-hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma
Clin. Cancer Res.,
April 1, 2008;
14(7):
2154 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yang, V. MacLeod, Y. Dai, Y. Khotskaya-Sample, Z. Shriver, G. Venkataraman, R. Sasisekharan, A. Naggi, G. Torri, B. Casu, et al.
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
Blood,
September 15, 2007;
110(6):
2041 - 2048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J. D. Shaughnessy Jr
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Blood,
March 1, 2007;
109(5):
2106 - 2111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Dalton and K. C. Anderson
Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma.
Clin. Cancer Res.,
November 15, 2006;
12(22):
6603 - 6610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tassone, P. Neri, J. L. Kutok, O. Tournilhac, D. D. Santos, E. Hatjiharissi, V. Munshi, S. Venuta, K. C. Anderson, S. P. Treon, et al.
A SCID-hu in vivo model of human Waldenstrom macroglobulinemia
Blood,
August 15, 2005;
106(4):
1341 - 1345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al.
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Blood,
August 1, 2005;
106(3):
1021 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ferrone and G. Sconocchia
A clinically relevant mouse model of human multiple myeloma?
Blood,
July 15, 2005;
106(2):
388 - 389.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tassone, P. Neri, D. R. Carrasco, R. Burger, V. S. Goldmacher, R. Fram, V. Munshi, M. A. Shammas, L. Catley, G. S. Jacob, et al.
A clinically relevant SCID-hu in vivo model of human multiple myeloma
Blood,
July 15, 2005;
106(2):
713 - 716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. O. Oyajobi, C. M. Shipman, and G. R. Mundy
Recent Insights into Myeloma Bone Disease
IBMS BoneKEy,
May 1, 2005;
2(5):
17 - 25.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Yin
Chondroitin Synthase 1 Is a Key Molecule in Myeloma Cell-Osteoclast Interactions
J. Biol. Chem.,
April 22, 2005;
280(16):
15666 - 15672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood,
February 15, 2005;
105(4):
1383 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, S. Ely, Y. Farooqi, M. Affer, D. F. Robbiani, M. Chesi, and P. L. Bergsagel
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
Blood,
May 1, 2004;
103(9):
3521 - 3528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model
Cancer Res.,
March 15, 2004;
64(6):
2016 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Johrer, K. Janke, J. Krugmann, M. Fiegl, and R. Greil
Transendothelial Migration of Myeloma Cells Is Increased by Tumor Necrosis Factor (TNF)-{alpha} via TNF Receptor 2 and Autocrine Up-Regulation of MCP-1
Clin. Cancer Res.,
March 15, 2004;
10(6):
1901 - 1910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, and B. Klein
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis
Blood,
March 1, 2004;
103(5):
1829 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-Y. Huang, H.-F. Tien, F.-H. Su, and S.-M. Hsu
Nonirradiated NOD/SCID-Human Chimeric Animal Model for Primary Human Multiple Myeloma: A Potential in Vivo Culture System
Am. J. Pathol.,
February 1, 2004;
164(2):
747 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mitsiades, N. S. Mitsiades, R. T. Bronson, D. Chauhan, N. Munshi, S. P. Treon, C. A. Maxwell, L. Pilarski, T. Hideshima, R. M. Hoffman, et al.
Fluorescence Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/NOD in Vivo Model: Biologic and Clinical Implications
Cancer Res.,
October 15, 2003;
63(20):
6689 - 6696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood,
June 15, 2003;
101(12):
4667 - 4679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Bergsagel
Prognostic Factors in Multiple Myeloma: It's in the Genes
Clin. Cancer Res.,
February 1, 2003;
9(2):
533 - 534.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, C. L. Johnson, S. C. Mahaffey, M. J. Wezeman, B. Barlogie, and J. Epstein
Antimyeloma efficacy of thalidomide in the SCID-hu model
Blood,
December 1, 2002;
100(12):
4162 - 4168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yang, S. Yaccoby, W. Liu, J. K. Langford, C. Y. Pumphrey, A. Theus, J. Epstein, and R. D. Sanderson
Soluble syndecan-1 promotes growth of myeloma tumors in vivo
Blood,
June 28, 2002;
100(2):
610 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-W. Peng, G. J. Ahmann, L. Pham, P. R. Greipp, R. Cattaneo, and S. J. Russell
Systemic therapy of myeloma xenografts by an attenuated measles virus
Blood,
October 1, 2001;
98(7):
2002 - 2007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Pearse, E. M. Sordillo, S. Yaccoby, B. R. Wong, D. F. Liau, N. Colman, J. Michaeli, J. Epstein, and Y. Choi
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
PNAS,
September 13, 2001;
(2001)
201394498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar, Y.-T. Tai, F. E. Davies, S. Lentzsch, M. Sattler, T. Hideshima, B. K. Lin, D. Gupta, Y. Shima, D. Chauhan, et al.
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
Blood,
July 15, 2001;
98(2):
428 - 435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, M. Bendandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L. W. Kwak, and H. K. Lyerly
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells
Blood,
October 15, 2000;
96(8):
2828 - 2833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
Blood,
April 15, 2000;
95(8):
2630 - 2636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Pilarski, G. Hipperson, K. Seeberger, E. Pruski, R. W. Coupland, and A. R. Belch
Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice
Blood,
February 1, 2000;
95(3):
1056 - 1065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, P. Eddlemon, N. Munshi, E. Anaissie, C. Wilson, M. Dhodapkar, et al.
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
N. Engl. J. Med.,
November 18, 1999;
341(21):
1565 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby and J. Epstein
The Proliferative Potential of Myeloma Plasma Cells Manifest in the SCID-hu Host
Blood,
November 15, 1999;
94(10):
3576 - 3582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Aoki, E. S. Jaffe, Y. Chang, K. Jones, J. Teruya-Feldstein, P. S. Moore, and G. Tosato
Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6
Blood,
June 15, 1999;
93(12):
4034 - 4043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Vacca, D. Ribatti, M. Presta, M. Minischetti, M. Iurlaro, R. Ria, A. Albini, F. Bussolino, and F. Dammacco
Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma
Blood,
May 1, 1999;
93(9):
3064 - 3073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Pearse, E. M. Sordillo, S. Yaccoby, B. R. Wong, D. F. Liau, N. Colman, J. Michaeli, J. Epstein, and Y. Choi
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
PNAS,
September 25, 2001;
98(20):
11581 - 11586.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
